Anaptysbio (ANAB) EBT Margin Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) EBT Margin Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -392.00 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 29,565.00 |
| 10 | Anaptysbio | 1.63 Bn | 1.34 Bn | - | -6,532.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -6,532.00 |
| Dec 31, 2025 | 15,398.00 |
| Sep 30, 2025 | 12,924.00 |
| Jun 30, 2025 | 25,188.00 |
| Mar 31, 2025 | 47,055.00 |
| Dec 31, 2024 | 38,108.00 |
| Sep 30, 2024 | 101,497.00 |
| Jun 30, 2024 | 72,637.00 |
| Mar 31, 2024 | 229,301.00 |
| Dec 31, 2023 | -2,612.00 |
| Sep 30, 2023 | 99,245.00 |
| Jun 30, 2023 | 104,348.00 |
| Mar 31, 2023 | 33,281.00 |
| Dec 31, 2022 | 263,239.00 |
| Sep 30, 2022 | -208,479.00 |
| Jun 30, 2022 | -219,364.00 |
| Mar 31, 2022 | -307,632.00 |
| Dec 31, 2021 | -313,115.00 |
| Mar 31, 2021 | -10,644.00 |
| Dec 31, 2020 | 73,224.00 |